Enduring Webcast of the 2012 CMSC Live Symposium: Personalized Medicine in Multiple Sclerosis: Examining the Path Forward
neuroscienceCME Webcast
Premiere Date: Monday, July 2, 2012This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, July 2, 2013
Note: Credit Is No Longer Available
 | Fred D. Lublin, MD, FAAN, FANA Saunders Family Professor of Neurology Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis Icahn School of Medicine at Mount Sinai New York, NY |
 | Robert P. Lisak, MD, FAAN, FRCP Professor of Neurology Professor of Immunology and Microbiology Wayne State University School of Medicine Chief of Neurology Harper University Hospital Detroit, MI |
 | Lawrence Steinman, MD Professor of Neurology and Neurological Sciences Stanford University Stanford, CA |
Co-provided by
The ever-evolving landscape of management strategies and therapeutics for the treatment of multiple sclerosis (MS) requires that clinicians stay abreast of not only novel therapies but also advances that could change the face of patient care. Using biomarkers in managing MS can aid clinicians in selecting therapies and accurately predicting the disease course.(1,2) Similarly, the ability to utilize MRI as a noninvasive biomarker for MS can enhance both diagnosis and the sequencing of targeted therapeutic agents for patients with MS.(2) In the context of personalized medicine and individualized therapy, implementation of appropriate sequencing strategies for the use of MS therapies—according to disease course and individual patient needs—can have a profound and positive impact on patient outcomes across the continuum of care.
This enduring webcast of the live symposium at CMSC on May 30, 2012 will endeavor to provide education to clinicians on personalized medicine in multiple sclerosis, including discussion of biomarkers and strategies for the sequencing of therapies across the continuum of care.
- Owen DR, Piccini P, Matthews PM. Towards molecular imaging of multiple sclerosis. Mult Scler. 2011;17(3):262-272. PMID: 21212087.
- Lublin FD. Promise of biomarkers for treatment selection and response [video, transcript]. Medscape.org Website. http://www.medscape.org/viewarticle/752537. Published November 1, 2011. Accessed December 5, 2011.
Please register in advance for these live Q & A sessions because we will be sending reminder e-mails and information prior to the events. Do not miss this opportunity to exchange your thoughts and questions with Drs. Lisak, Lublin, and Steinman!
These 30-minute Q & A sessions are not certified for CE credit.
To provide education to clinicians on personalized medicine in multiple sclerosis, including discussion of biomarkers and strategies for the sequencing of therapies across the continuum of care.
At the end of this CE activity, participants should be able to:
- Evaluate the “state of the art” of biomarkers to facilitate personalized treatment strategies for the management of MS, in anticipation of the future integration of biomarkers into clinical practice.
- Improve the use of data derived from MRI in clinical practice (as a noninvasive biomarker candidate) to aid in the diagnosis and targeted treatment for patients with MS.
- Examine the evidence for the sequencing of therapies in the management of MS, and implement personalized sequencing strategies for application to clinical practice.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Review the “state of the art” of biomarkers in anticipation of the future integration of biomarkers into clinical practice.
- Increase the clinical use of data derived from MRI in clinical practice (as a noninvasive biomarker candidate) to aid in the diagnosis and targeted treatment for patients with MS.
- Examine the evidence for the sequencing of therapies in the management of MS, and implement personalized sequencing strategies for application to clinical practice.
USF Health and CME Outfitters, LLC gratefully acknowledge an educational grant from Biogen Idec in support of this CE activity.
Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other health care professionals with an interest in multiple sclerosis.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.25 contact hours (0.125 CEUs)
Universal Activity Number: 0376-0000-12-014-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.neuroscienceCME.com/TST703 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Lublin has disclosed that he receives grants/research support from Acorda Therapeutics, Inc; Biogen Idec; Celgene Corporation, National Institutes of Health; National Multiple Sclerosis Society; Novartis Pharmaceuticals Corporation, sanofi-aventis US, LLC, and Teva Neurosciences, Inc. He serves as a consultant to Abbott Laboratories; Acorda Therapeutics, Actelion Pharmaceuticals Ltd; Allozyne Inc., AVANIR Pharmaceuticals Inc.; Bayer HealthCare Pharmaceuticals Inc.; Biogen Idec, Bristol-Myers Squibb; Celgene Corporation; Coronado Bioscience; EMD Serono, Inc; Genmab, Inc.; Genzyme Corporation; Johnson & Johnson Services, Inc.; Medicinova, Inc.; MedImmune, LLC; MorphoSys; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Questcor Pharmaceuticals, Inc.; Revalesio Corporation; Roche; sanofi-aventis US LLC; and Teva Neurosciences, Inc. He as disclosed a financial interest/stock ownership in Cognition Pharmaceuticals, Inc.
Dr. Lisak has disclosed that he receives grants/research support from AVANIR Pharmaceuticals Inc.; Biogen Idec, Genzyme Corporation; Novartis Pharmaceuticals Corporation; Questcor Pharmaceuticals, Inc.; and Teva Neurosciences, Inc. He has received honoraria/speakers fees from Questcor Pharmaceuticals, Inc. He serves as a consultant for Novartis Pharmaceuticals Corporation; Questcor Pharmaceuticals, Inc.; and Teva Neurosciences, Inc.
Dr. Steinman has disclosed that he serves as a consultant to Biogen Idec and Bayer Corporation.
Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.
Richard Isaacson, MD (content/peer reviewer) has disclosed that he receives grants from the National Institutes of Health Clinical Research LRP. He is on the speakers bureau of and is a consultant to Accera and Novartis.
Ruth Cody, BSN, RN-BC (content/peer reviewer) has no disclosures
to report.
Nancy Jennings, MSN, MBA, MHA, RNC (content/peer reviewer) has no
disclosures to report.
Catherine F. Murray (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
USF Health, CME Outfitters, LLC, the faculty, and Biogen Idec do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Equal Opportunity Statement:
Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-039-070212-29
